TAK-659 hydrochloride
CAS No. 1952251-28-3
TAK-659 hydrochloride( Mivavotinib | TAK 659 | TAK659 )
Catalog No. M13056 CAS No. 1952251-28-3
TAK-659 hydrochloride (Mivavotinib, TAK659) is a potent, selective and orally available SYK inhibitor with IC50 of 3.2 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 72 | In Stock |
|
| 10MG | 107 | In Stock |
|
| 25MG | 217 | In Stock |
|
| 50MG | 323 | In Stock |
|
| 100MG | 500 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTAK-659 hydrochloride
-
NoteResearch use only, not for human use.
-
Brief DescriptionTAK-659 hydrochloride (Mivavotinib, TAK659) is a potent, selective and orally available SYK inhibitor with IC50 of 3.2 nM.
-
DescriptionTAK-659 hydrochloride (Mivavotinib, TAK659) is a potent, selective and orally available SYK inhibitor with IC50 of 3.2 nM; displays 36, 42 and 23-fold selectivity over JAK3, ZAP70 and VEGFR2, respectively; also potently inhibits FLT-3; inhibits cellular proliferation in SYK-dependent DLBCL and FLT3-dependent AML cell lines, demonstrates potent tumor growth inhibition in the FLT3-dependent MV4-11 xenograft models.Blood Cancer Phase 2 Clinical(In Vitro):TAK-659 hydrochloride inhibits cellular proliferation in SYK-dependent DLBCL and FLT3-dependent AML cell lines.TAK-659 hydrochloride (5 μM; 1-24 hours) induces Casp3 activation in the LMP2A/MYC cells which was readily apparent at 4 h and reached maximum levels at 8 h of treatment.TAK-659 hydrochloride (0.01-10 μM; 1 hour) stimulates expression of phospho-Syk at Tyr525 and Tyr352 and phospho-ERK1/2 increased in Ramos cells.(In Vivo):TAK-659 hydrochloride (100 mg/kg/day; p.o.; daily, for 10 days) treatment totally abrogates splenomegaly and tumor development in LMP2A/MYC mice in both pretumor and tumor cell transfer experiments.TAK-659 hydrochloride treatment kills tumor cells, but not host cells within the spleen and tumors.TAK-659 hydrochloride treatment abrogates metastasis of tumor cells into bone marrow.
-
In VitroTAK-659 hydrochloride inhibits cellular proliferation in SYK-dependent DLBCL and FLT3-dependent AML cell lines.TAK-659 hydrochloride (5 μM; 1-24 hours) induces Casp3 activation in the LMP2A/MYC cells which was readily apparent at 4 h and reached maximum levels at 8 h of treatment.TAK-659 hydrochloride (0.01-10 μM; 1 hour) stimulates expression of phospho-Syk at Tyr525 and Tyr352 and phospho-ERK1/2 increased in Ramos cells. Apoptosis Analysis Cell Line:LMP2A/MYC cells Concentration:5 μM Incubation Time:1 hour, 2 hours, 4 hours, 8 hours, 24 hours Result:Induced apoptosis in LMP2A/MYC lymphoma cells.Western Blot Analysis Cell Line: Ramos cells Concentration: 0.01 μM,0.1 μM,1 μM,10 μM Incubation Time:1 hour Result:Enhanced expression of phospho-Syk at Tyr525 and Tyr352 and phospho-ERK1/2 in stimulated Ramos cells.
-
In VivoTAK-659 hydrochloride (100 mg/kg/day; p.o.; daily, for 10 days) treatment totally abrogates splenomegaly and tumor development in LMP2A/MYC mice in both pretumor and tumor cell transfer experiments.TAK-659 hydrochloride treatment kills tumor cells, but not host cells within the spleen and tumors.TAK-659 hydrochloride treatment abrogates metastasis of tumor cells into bone marrow. Animal Model:LMP2A/MYC double transgenic mice Dosage:100 mg/kg/day Administration:Oral gavage; for 10 daysResult:Inhibited LMP2A-induced tumor cell survival in vivo.
-
SynonymsMivavotinib | TAK 659 | TAK659
-
PathwayAngiogenesis
-
TargetSyk
-
RecptorFLT3|JAK3|Syk|VEGFR2|ZAP70
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number1952251-28-3
-
Formula Weight380.852
-
Molecular FormulaC17H22ClFN6O
-
Purity>98% (HPLC)
-
SolubilityDMSO: <1 mg/mL; Ethanol: <1 mg/mL; Water: 4 mg/mL (10.5 mM), warmed ( < 1 mg/ml refers to the product slightly soluble or insoluble )
-
SMILESCN1C=C(C=N1)C2=NC(=C(C3=C2C(=O)NC3)F)NC4CCCCC4N.Cl
-
Chemical Name6-(((1R,2S)-2-aminocyclohexyl)amino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one hydrochloride
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lam B, et al. Bioorg Med Chem Lett. 2016 Dec 15;26(24):5947-5950.
2. Purroy N, et al. Oncotarget. 2017 Jan 3;8(1):742-756.
molnova catalog
related products
-
Sovleplenib
Sovleplenib (HMPL523) is an orally available, selective and potent inhibitor of the splenic tyrosine kinase SYK with an IC50 of 25 nM.Sovleplenib has antitumor activity and may be used in studies of immune thrombocytopenia (ITP).
-
MNS
MNS is a tyrosine kinases inhibitor inhibits Syk Src p97 with IC50 of 2.5 μM 29.3 μM and 1.7 μM respectively.
-
Mitapivat
Mitapivat, also known as PKM2 activator 1020 is a PKM2 activator (pyruvate kinase activator) for the treatment of pyruvate kinase deficiency.
Cart
sales@molnova.com